XOMA CORPORATION

Analyst Reco. XOMA Corporation

Equities

XOMA

US98419J2069

Market Closed - Nasdaq Other stock markets 21:00:00 27/06/2024 BST			5-day change	1st Jan Change
22.9 ^USD	+1.24%		-11.24%	+23.78%

06-12	XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher	MT
05-09	Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	04-29	MT
HC Wainwright Adjusts Price Target on XOMA to $74 From $69, Maintains Buy Rating	09/08/23	MT
XOMA : Wedbush Suspended Coverage on XOMA	11/10/21	MT
XOMA : HC Wainwright Adjusts XOMA's Price Target to $69 from $56, Keeps Buy Rating	08/10/21	MT
XOMA : Aegis Capital Adjusts XOMA Price Target to $56 From $60, Maintains Buy Rating	09/09/21	MT
Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41	07/09/21	MT
XOMA : Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41	07/09/21	MT
XOMA : Aegis Capital Starts XOMA at Buy with $20.68 Price Target	29/06/21	MT
XOMA : Wedbush Adjusts XOMA's Price Target to $41 From $36, Citing Iscalimab, Cetrelimab Projections; Outperform Rating Kept	19/03/21	MT
XOMA : Wedbush Adjusts XOMA's Price Target to $36 From $29 on Vicineum Sales Forecast, Keeps Outperform Rating	27/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer